Immedica initiates a phase 3 pediatric study for Loargys® (pegzilarginase) in arginase 1 deficiency
Stockholm, September 18, 2024: Immedica announces today that the first subject has been dosed in the phase 3 pediatric study (CAEB1102-301A) for Loargys® (pegzilarginase) in arginase 1 deficiency (ARG1-D). Loargys is approved in the EU and Great Britain for the treatment of ARG1-D in adults, adolescents and children aged 2 years and older. The initiation of a clinical study in children below 2 years of age is of high importance in this progressive disease exposing patients to elevated toxic levels of arginine from birth. Study CAEB1102-301A is a phase 3, open-label, single-arm, non-